Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

Authors Wei Y, Guo J, Zheng X, Wu J, Zhou Y, Yu Y, Ye Y, Zhang L, Zhao L, Zou Y, Zheng W, Liu H

Received 16 April 2014

Accepted for publication 24 May 2014

Published 1 August 2014 Volume 2014:9(1) Pages 3623—3630


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Yumeng Wei,1,* Jianmin Guo,2,* Xiaoli Zheng,2,* Jun Wu,3 Yang Zhou,1 Yu Yu,4 Yun Ye,1 Liangke Zhang,4 Ling Zhao1

School of Pharmacy, 2Institute of Basic Medical Sciences, Luzhou Medical College, Luzhou City, Sichuan Province, People’s Republic of China; 3Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Greenville, SC, USA; 4School of Pharmacy, Chongqing Medical University, Chongqing, People’s Republic of China

*These authors contributed equally to this work

Abstract: Baicalin (BA) is a major constituent of Scutellaria baicalensis Georgi, a medicinal herb. Previous pharmacokinetic studies of BA showed its low oral bioavailability. The aim of the present study was to develop a novel BA-loaded liposome (BA-LP) to enhance oral bioavailability. BA-LP, composed of BA, Tween® 80, Phospholipon® 90H, and citric acid at weight ratio of 96/50/96/50, respectively, was prepared by the effervescent dispersion technique and characterized in terms of morphology, size, zeta potential, encapsulation efficiency, and the in vitro release. Pharmacokinetics and biodistribution studies were carried out in rats after oral administration of BA-LP and a carboxymethyl cellulose suspension containing BA (BA-CMC) as a control. BA-LP exhibited a spherical shape by transmission electron microscopy observation. BA-LP had a mean particle size of 373±15.5 nm, zeta potential of -20.1±0.22 mV, and encapsulation efficiency of 82.7%±0.59%. The BA-LP showed a sustained-release behavior, and the in vitro drug-release kinetic model fit well with the Weibull distribution equation: lnln (1/(1-Q)) =0.609 lnt -1.230 (r=0.995). The oral bioavailability and the peak concentration of the BA-LP was threefold and 2.82-fold that of BA-CMC, respectively. The in vivo distribution results indicated that drug concentrations were significantly increased in the liver, kidney, and lung in the case of BA-LP, which were 5.59-fold, 2.33-fold, and 1.25-fold higher than those of BA-CMC, respectively. In conclusion, the study suggested that BA-LP might be a potential oral drug delivery system to improve bioavailability of BA. 

Keywords: nanoliposomes, bioavailability, nanoliposomes, in vitro release, bioavailability, in vivo evaluation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]